NCT00036114
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
ConditionsAlzheimer Disease
Drugsaripiprazole
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Alzheimer Disease
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Locations
- 1
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Institutionalized patients with Alzheimer's
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeAlzheimer DiseaseNCT00041678Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar DisorderBipolar DisorderNCT00036101Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar DisorderBipolar I DisorderNCT00046384Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed
Phase 3
Study of Aripiprazole in Patients With a History of Bipolar DisorderBipolar DisorderNCT00036348Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting
Not Applicable
To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorderHealth Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disordersCTRI/2021/04/032524GMC medical college